References
- Cheng H, Harris RC. The glomerulus—a view from the outside—the podocyte. Int J Biochem Cell Biol. 2010;42:1380–1387.
- Wickman C, Kramer H. Obesity and kidney disease: potential mechanisms. Semin Nephrol. 2013;33:14–22.
- Wanner C, Greiber S, Kramer-Guth A, et al. Lipids and progression of renal disease: role of modified low density lipoprotein and lipoprotein(a). Kidney Int Suppl. 1997;63:S102–S106.
- Lee HS, Song CY. Oxidized low-density lipoprotein and oxidative stress in the development of glomerulosclerosis. Am J Nephrol. 2009;29:62–70.
- Galle J, Heermeier K, Wanner C. Atherogenic lipoproteins, oxidative stress, and cell death. Kidney Int Suppl. 1999;71:S62–S65.
- Mulec H, Johnsen SA, Wiklund O, et al. Cholesterol: a renal risk factor in diabetic nephropathy? Am J Kidney Dis. 1993;22:196–201.
- Li WG, Li NN Podocyte respose to injure. J Clin Pediatric. 2012;30(11):1091–1094
- Mundel P, Shankland SJ Podocyte biology and response to injury J Am Soc Nephrol. 2002;13:3005–3015
- Taylor F, Huffman MD, Macedo AF, et al. Statins for the primary prevention of cardiovascular disease. Cochrane Database Syst Rev. 2013;1:CD004816.
- Gao L, Wang W, Zucker IH. Simvastatin inhibits central sympathetic outflow in heart failure by a nitric-oxide synthase mechanism. J Pharmacol Exp Ther. 2008;326:278–285.
- Rossoni LV, Wareing M, Wenceslau CF, et al. Acute simvastatin increases endothelial nitric oxide synthase phosphorylation via AMP-activated protein kinase and reduces contractility of isolated rat mesenteric resistance arteries. Clin Sci (Lond) 2011;121:449–458.
- Wang W, Zhao C, Zhou J, et al. Simvastatin ameliorates liver fibrosis via mediating nitric oxide synthase in rats with non-alcoholic steatohepatitis-related liver fibrosis. PLoS One 2013;8:e76538.
- Lavi R, Zhu XY, Chade AR, et al. Simvastatin decreases endothelial progenitor cell apoptosis in the kidney of hypertensive hypercholesterolemic pigs. Arterioscler Thromb Vasc Biol. 2010;30:976–783.
- Andrade VL, Valle IB, Sandrim VC. Simvastatin therapy decreases MMP-9 levels in obese women. J Clin Pharmacol. 2013;53:1072–1077.
- Gutwein P, Abdel-Bakky MS, Doberstein K, et al. CXCL16 and oxLDL are induced in the onset of diabetic nephropathy. J Cell Mol Med. 2009;13:3809–3825.
- Nosadini R, Tonolo G. Role of oxidized low density lipoproteins and free fatty acids in the pathogenesis of glomerulopathy and tubulointerstitial lesions in type 2 diabetes. Nutr Metab Cardiovasc Dis. 2011;21:79–85.
- Stitt-Cavanagh E, MacLeod L, Kennedy C. The podocyte in diabetic kidney disease. Sci. World J. 2009;9:1127–1139.
- Fernando RL, Varghese Z, Moorhead JF. Oxidation of low-density lipoproteins by rat mesangial cells and the interaction of oxidized low-density lipoproteins with rat mesangial cells in vitro. Nephrol Dial Transplant. 1993;8:512–518.
- Xia Y, Entman ML, Wang Y. Critical role of CXCL16 in hypertensive kidney injury and fibrosis. Hypertension 2013;62:1129–1137.
- Garcia GE, Truong LD, Li P, et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am J Pathol. 2007;170:1485–1496.
- Teramoto K, Negoro N, Kitamoto K, et al. Microarray analysis of glomerular gene expression in murine lupus nephritis. J Pharmacol Sci. 2008;106:56–67.
- Gutwein P, Abdel-Bakky MS, Schramme A, et al. CXCL16 is expressed in podocytes and acts as a scavenger receptor for oxidized low-density lipoprotein. Am J Pathol. 2009;174:2061–2072.
- Wang L, Sun S, Zhou A, et al. oxLDL-induced lipid accumulation in glomerular podocytes: role of INF-γ, CXCL16 and ADAM10. Cell Biochem Biophys. 2014;70:529–538.
- Smith C, Halvorsen B, Otterdal K, et al. High levels and inflammatory effects of soluble CXC ligand 16 (CXCL16) in coronary artery disease: down-regulatory effects of statins. Cardiovasc Res. 2008;79:195–203.
- Bussolati B, Deregibus MC, Fonsato V, et al. Statins prevent oxidized LDL-induced injury of glomerular podocytes by activating the phosphatidylinositol3-kinase/AKT signaling pathway. J Am Soc Nephrol. 2005;16:1936–1947.
- Tonolo G, Velussi M, Brocco E, et al. Simvastatin maintains steady patterns of GFR and improves AER and expression of slit diaphragm proteins in type II diabetes. Kidney Int. 2006;70:177–186.
- Chen S, Chen H, Liu Q. Experimental study on the protection against podocyte injury by simvastatin in diabetes mellitus rats. Chin J Diabetes. 2009;17:861–863.
- Shi Q, Feng L, Lu X, et al. Simvastatin effects on nephrin gene expression in diabetic rat kidney. Guangdong Med J. 2006;27:1799–1801.